Skip to main content
Top
Published in: Clinical and Experimental Medicine 8/2023

04-11-2023 | Lymphoma | Research

A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome

Authors: Tayebeh Mohammadi, Gholamreza Azizi, Hosein Rafiemanesh, Pouria Farahani, Matineh Nirouei, Marzieh Tavakol

Published in: Clinical and Experimental Medicine | Issue 8/2023

Login to get access

Abstract

The hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease originally described as Job syndrome. The fundamental causative variant of the HIES is an autosomal dominant mutation in the signal transducer and activator of transcription 3 (STAT3) gene. It is characterized by recurrent staphylococcal cold skin abscess, sinopulmonary infection, eczema, head and face anomalies, frequent bone fractures, eosinophilia and extremely high serum IgE levels (IgE ≥ 2000 IU/mL). However, multiple other genetic defects are also known as HIES-like disorders. Apart from infectious manifestations, STAT3, DOCK8 and TYK2 gene mutations are associated with various malignancies. The most common malignancies reported in these patients are lymphomas, including Hodgkin’s and non-Hodgkin’s lymphomas (NHL) of B and T cells. This systematic review aimed to investigate the prevalence of malignancies in HIES and the factors associated with malignancy in these patients. In this survey, all articles published until April 1st, 2023, in Scopus, PubMed and Web of Science databases based on three groups of keywords related to HIES syndrome and malignancy were reviewed by three different researchers. Finally, 26 articles were evaluated from which 24 papers were meta-analyzed. In the current study, the demographic information of 1133 patients with HIES, which was mentioned in 24 articles enrolled in the project, was collected, and the information related to patients who had malignancy was analyzed and meta-analyzed. A total of 96 patients out of 1133 studied patients had at least one type of malignancy, the overall prevalence of malignancies reported in the articles was 6.5% (95% confidence interval 4.1–9%), and the total prevalence of malignancy in patients with NHL type and patients with squamous cell carcinoma (SCC) was 2.9% (95% confidence interval 1.7–4.4%) and 2.2% (95% confidence interval 0.3–4.1%), respectively. The results of this study indicated that in 6.5% of cases, HIES was complicated with malignancy, and considering the higher rate of these malignancies in women as well as in DOCK8 mutation sufferers, it is necessary for physicians to be aware of this association and includes malignancy screening in follow-up and periodic examinations of these patients. Indeed, more studies in this field will help to clarify the precise figures and predisposing factors of the relationship between HIES and malignancy.
Literature
1.
go back to reference Davis S, Schaller J, Wedgwood R, Harvard M. Job’s syndrome: recurrent," cold", staphylococcal abscesses. The Lancet. 1966;287(7445):1013–5.CrossRef Davis S, Schaller J, Wedgwood R, Harvard M. Job’s syndrome: recurrent," cold", staphylococcal abscesses. The Lancet. 1966;287(7445):1013–5.CrossRef
2.
go back to reference Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14:1–10.CrossRef Yong PF, Freeman AF, Engelhardt KR, Holland S, Puck JM, Grimbacher B. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14:1–10.CrossRef
3.
4.
go back to reference Chu EY, Freeman AF, Jing H, Cowen EW, Davis J, Su HC, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148(1):79–84.CrossRefPubMed Chu EY, Freeman AF, Jing H, Cowen EW, Davis J, Su HC, et al. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol. 2012;148(1):79–84.CrossRefPubMed
5.
go back to reference Gharehzadehshirazi A, Amini A, Rezaei N. Hyper IgE syndromes: a clinical approach. Clin Immunol. 2022;237: 108988.CrossRefPubMed Gharehzadehshirazi A, Amini A, Rezaei N. Hyper IgE syndromes: a clinical approach. Clin Immunol. 2022;237: 108988.CrossRefPubMed
6.
go back to reference Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508–20.CrossRefPubMed Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508–20.CrossRefPubMed
8.
go back to reference Winslow A, Jalazo ER, Evans A, Winstead M, Moran T. A de novo cause of PGM3 deficiency treated with hematopoietic stem cell transplantation. J Clin Immunol. 2022;42(3):691–4.CrossRefPubMedPubMedCentral Winslow A, Jalazo ER, Evans A, Winstead M, Moran T. A de novo cause of PGM3 deficiency treated with hematopoietic stem cell transplantation. J Clin Immunol. 2022;42(3):691–4.CrossRefPubMedPubMedCentral
9.
10.
go back to reference Ravichandran N, Uppuluri R, Swaminathan VV, Ramanan KM, Meena S, Varla H, et al. Management of peripheral T-cell lymphoma in children and adolescents including STAT 3 mutation hyper-IgE syndrome: one size does not fit all. J of Pediatr Hematol/Oncol. 2022;44(4):e849–e54. Ravichandran N, Uppuluri R, Swaminathan VV, Ramanan KM, Meena S, Varla H, et al. Management of peripheral T-cell lymphoma in children and adolescents including STAT 3 mutation hyper-IgE syndrome: one size does not fit all. J of Pediatr Hematol/Oncol. 2022;44(4):e849–e54.
11.
go back to reference Al Shekaili L, Sheikh F, Al Gazlan S, Al Dhekri H, Al Mousa H, Al Ghonaium A, et al. Novel mutation in DOCK8- HIES with severe phenotype and successful transplantation. Clin Immunol. 2017;178:39–44. Al Shekaili L, Sheikh F, Al Gazlan S, Al Dhekri H, Al Mousa H, Al Ghonaium A, et al. Novel mutation in DOCK8- HIES with severe phenotype and successful transplantation. Clin Immunol. 2017;178:39–44.
12.
go back to reference Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N Engl J Med. 1999;170(3):319–333. Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections—an autosomal dominant multisystem disorder. N Engl J Med. 1999;170(3):319–333.
13.
go back to reference Moin M, Farhoudi A, Movahedi M, Rezaei N, Pourpak Z, Yeganeh M, et al. The clinical and laboratory survey of Iranian patients with hyper-IgE syndrome. Scand J Infect Dis. 2006;38(10):898–903.CrossRefPubMed Moin M, Farhoudi A, Movahedi M, Rezaei N, Pourpak Z, Yeganeh M, et al. The clinical and laboratory survey of Iranian patients with hyper-IgE syndrome. Scand J Infect Dis. 2006;38(10):898–903.CrossRefPubMed
14.
go back to reference Jiao H, Tóth B, Erdős M, Fransson I, Rákóczi É, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46(1):202–6.CrossRefPubMed Jiao H, Tóth B, Erdős M, Fransson I, Rákóczi É, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups. Mol Immunol. 2008;46(1):202–6.CrossRefPubMed
15.
go back to reference Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124(6):1289-302. e4.CrossRefPubMedPubMedCentral Engelhardt KR, McGhee S, Winkler S, Sassi A, Woellner C, Lopez-Herrera G, et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol. 2009;124(6):1289-302. e4.CrossRefPubMedPubMedCentral
16.
go back to reference Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046–55.CrossRefPubMedPubMedCentral Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046–55.CrossRefPubMedPubMedCentral
17.
go back to reference Chandesris M-O, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine. 2012;91(4):e1–19.CrossRefPubMed Chandesris M-O, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine. 2012;91(4):e1–19.CrossRefPubMed
18.
go back to reference Al-Herz W, Ragupathy R, Massaad MJ, Nanda A, Engelhardt KR, Grimbacher B, et al. Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. Clin Immunol. 2012;143(3):266–72.CrossRefPubMedPubMedCentral Al-Herz W, Ragupathy R, Massaad MJ, Nanda A, Engelhardt KR, Grimbacher B, et al. Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. Clin Immunol. 2012;143(3):266–72.CrossRefPubMedPubMedCentral
19.
go back to reference Sanal O, Jing H, Ozgur T, Ayvaz D, Strauss-Albee DM, Ersoy-Evans S, et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol. 2012;32:698–708.CrossRefPubMedPubMedCentral Sanal O, Jing H, Ozgur T, Ayvaz D, Strauss-Albee DM, Ersoy-Evans S, et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J Clin Immunol. 2012;32:698–708.CrossRefPubMedPubMedCentral
20.
go back to reference Alsum Z, Hawwari A, Alsmadi O, Al-Hissi S, Borrero E, Abu-staiteh A, et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty five patients. J Clin Immunol. 2013;33:55–67.CrossRefPubMed Alsum Z, Hawwari A, Alsmadi O, Al-Hissi S, Borrero E, Abu-staiteh A, et al. Clinical, immunological and molecular characterization of DOCK8 and DOCK8-like deficient patients: single center experience of twenty five patients. J Clin Immunol. 2013;33:55–67.CrossRefPubMed
21.
go back to reference Wolach O, Kuijpers T, Ben-Ari J, Gavrieli R, Feinstein-Goren N, Alders M, et al. Variable clinical expressivity of STAT3 mutation in hyperimmunoglobulin E syndrome: genetic and clinical studies of six patients. J Clin Immunol. 2014;34:163–70.CrossRefPubMed Wolach O, Kuijpers T, Ben-Ari J, Gavrieli R, Feinstein-Goren N, Alders M, et al. Variable clinical expressivity of STAT3 mutation in hyperimmunoglobulin E syndrome: genetic and clinical studies of six patients. J Clin Immunol. 2014;34:163–70.CrossRefPubMed
22.
go back to reference Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options-a review of 136 patients. J Clin Immunol. 2015;35:189–98.CrossRefPubMed Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options-a review of 136 patients. J Clin Immunol. 2015;35:189–98.CrossRefPubMed
23.
go back to reference Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–12.CrossRefPubMedPubMedCentral Engelhardt KR, Gertz ME, Keles S, Schäffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–12.CrossRefPubMedPubMedCentral
24.
go back to reference Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8.CrossRefPubMed Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8.CrossRefPubMed
25.
go back to reference Gernez Y, Freeman AF, Holland SM, Garabedian E, Patel NC, Puck JM, et al. Autosomal dominant hyper-IgE syndrome in the USIDNET registry. J Allergy Clin Immunol Pract. 2018;6(3):996–1001.CrossRefPubMed Gernez Y, Freeman AF, Holland SM, Garabedian E, Patel NC, Puck JM, et al. Autosomal dominant hyper-IgE syndrome in the USIDNET registry. J Allergy Clin Immunol Pract. 2018;6(3):996–1001.CrossRefPubMed
26.
go back to reference Jacob M, Bin Khalaf D, Alhissi S, Arnout R, Alsaud B, Al-Mousa H, et al. Quantitative profiling of cytokines and chemokines in DOCK 8-deficient and atopic dermatitis patients. Allergy. 2019;74(2):370–9.CrossRefPubMed Jacob M, Bin Khalaf D, Alhissi S, Arnout R, Alsaud B, Al-Mousa H, et al. Quantitative profiling of cytokines and chemokines in DOCK 8-deficient and atopic dermatitis patients. Allergy. 2019;74(2):370–9.CrossRefPubMed
27.
go back to reference Tavassoli M, Abolhassani H, Yazdani R, Ghadami M, Azizi G, Abdolrahim Poor Heravi S, et al. The first cohort of Iranian patients with hyper immunoglobulin E syndrome: a long‐term follow‐up and genetic analysis. Pediatric Allergy Immunol 30(4):469–78CrossRef Tavassoli M, Abolhassani H, Yazdani R, Ghadami M, Azizi G, Abdolrahim Poor Heravi S, et al. The first cohort of Iranian patients with hyper immunoglobulin E syndrome: a long‐term follow‐up and genetic analysis. Pediatric Allergy Immunol 30(4):469–78CrossRef
28.
go back to reference Maffeis M, Notarangelo LD, Schumacher RF, Soncini E, Soresina A, Lanfranchi A, et al. Primary immunodeficiencies and oncological risk: the experience of the Children’s Hospital of Brescia. Front Pediatr. 2019;7:232.CrossRefPubMedPubMedCentral Maffeis M, Notarangelo LD, Schumacher RF, Soncini E, Soresina A, Lanfranchi A, et al. Primary immunodeficiencies and oncological risk: the experience of the Children’s Hospital of Brescia. Front Pediatr. 2019;7:232.CrossRefPubMedPubMedCentral
29.
go back to reference Kasap N, Celik V, Isik S, Cennetoglu P, Kiykim A, Eltan SB, et al. A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis. Clin Immunol. 2021;223:108645.CrossRefPubMed Kasap N, Celik V, Isik S, Cennetoglu P, Kiykim A, Eltan SB, et al. A set of clinical and laboratory markers differentiates hyper-IgE syndrome from severe atopic dermatitis. Clin Immunol. 2021;223:108645.CrossRefPubMed
30.
go back to reference Frede N, Rojas-Restrepo J, Caballero Garcia de Oteyza A, Buchta M, Hübscher K, Gámez-Díaz L, et al. Genetic analysis of a cohort of 275 patients with hyper-IgE syndromes and/or chronic mucocutaneous candidiasis. J Clin Immunol. 2021;41(8):1804–38.CrossRefPubMedPubMedCentral Frede N, Rojas-Restrepo J, Caballero Garcia de Oteyza A, Buchta M, Hübscher K, Gámez-Díaz L, et al. Genetic analysis of a cohort of 275 patients with hyper-IgE syndromes and/or chronic mucocutaneous candidiasis. J Clin Immunol. 2021;41(8):1804–38.CrossRefPubMedPubMedCentral
31.
go back to reference Urban A, Wyndham NLPCMCRMW, Pittaluga S, Irini CWPCTHDNP, Freeman AF. Malignancy in STAT3 deficient hyper IgE syndrome. J Clin Immunol. 2022;42(3):699–702.CrossRefPubMed Urban A, Wyndham NLPCMCRMW, Pittaluga S, Irini CWPCTHDNP, Freeman AF. Malignancy in STAT3 deficient hyper IgE syndrome. J Clin Immunol. 2022;42(3):699–702.CrossRefPubMed
32.
33.
go back to reference Urdinez L, Erra L, Palma AM, Mercogliano MF, Fernandez JB, Prieto E, et al. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: a single center experience. Front Immunol. 2022;13:1020927.CrossRefPubMedPubMedCentral Urdinez L, Erra L, Palma AM, Mercogliano MF, Fernandez JB, Prieto E, et al. Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: a single center experience. Front Immunol. 2022;13:1020927.CrossRefPubMedPubMedCentral
34.
go back to reference Aliyath A, Eni-Olotu A, Donaldson N, Trivedi P. Malignancy-associated immune responses: lessons from human inborn errors of immunity. Immunology. 2023. Aliyath A, Eni-Olotu A, Donaldson N, Trivedi P. Malignancy-associated immune responses: lessons from human inborn errors of immunity. Immunology. 2023.
35.
go back to reference Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: a double edged sword. Cytokine. 2017;98:42–50.CrossRefPubMed Avalle L, Camporeale A, Camperi A, Poli V. STAT3 in cancer: a double edged sword. Cytokine. 2017;98:42–50.CrossRefPubMed
37.
go back to reference Oikonomopoulou C, Goussetis E. Autosomal dominant hyper-IgE syndrome: when hematopoietic stem cell transplantation should be considered? Pediatr Transpl. 2020;24(5):e13699.CrossRef Oikonomopoulou C, Goussetis E. Autosomal dominant hyper-IgE syndrome: when hematopoietic stem cell transplantation should be considered? Pediatr Transpl. 2020;24(5):e13699.CrossRef
38.
go back to reference Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–19.CrossRefPubMedPubMedCentral Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine (Baltimore). 2012;91(4):e1–19.CrossRefPubMedPubMedCentral
39.
go back to reference Leonard G, Posadas E, Herrmann P, Anderson V, Jaffe E, Holland S, et al. Non-Hodgkin’s lymphoma in Job’s syndrome: a case report and literature review. Leuk Lymphoma. 2004;45(12):2521–5.CrossRefPubMed Leonard G, Posadas E, Herrmann P, Anderson V, Jaffe E, Holland S, et al. Non-Hodgkin’s lymphoma in Job’s syndrome: a case report and literature review. Leuk Lymphoma. 2004;45(12):2521–5.CrossRefPubMed
40.
go back to reference Kiaee F, Azizi G, Rafiemanesh H, Zainaldain H, Sadaat Rizvi F, Alizadeh M, et al. Malignancy in common variable immunodeficiency: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2019;15(10):1105–13.CrossRefPubMed Kiaee F, Azizi G, Rafiemanesh H, Zainaldain H, Sadaat Rizvi F, Alizadeh M, et al. Malignancy in common variable immunodeficiency: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2019;15(10):1105–13.CrossRefPubMed
41.
go back to reference Freeman AF, Holland SM. Clinical manifestations of hyper IgE syndromes. Dis Mark. 2010;29:123–30.CrossRef Freeman AF, Holland SM. Clinical manifestations of hyper IgE syndromes. Dis Mark. 2010;29:123–30.CrossRef
42.
go back to reference Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127(6):1329-41. e4.CrossRefPubMed Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127(6):1329-41. e4.CrossRefPubMed
Metadata
Title
A systematic review regarding the prevalence of malignancy in patients with the hyper-IgE syndrome
Authors
Tayebeh Mohammadi
Gholamreza Azizi
Hosein Rafiemanesh
Pouria Farahani
Matineh Nirouei
Marzieh Tavakol
Publication date
04-11-2023
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 8/2023
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01228-5

Other articles of this Issue 8/2023

Clinical and Experimental Medicine 8/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine